Multiple metabolic pathways are predictive of ricin intoxication in a rat model by D’Elia, Riccardo et al.
 
 
University of Birmingham
Multiple metabolic pathways are predictive of ricin
intoxication in a rat model
D’Elia, Riccardo; Goodchild, Sarah; Winder, Catherine L. ; Southam, Andrew; Weber, Ralf;
Stahl, Fiona; Docx, Cerys; Patel, Vikesh; Green, A. Christopher; Viant, Mark; Lukaszewski,
Roman; Dunn, Warwick
DOI:
10.1007/s11306-019-1547-9
License:
Other (please provide link to licence statement
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
D’Elia, R, Goodchild, S, Winder, CL, Southam, A, Weber, R, Stahl, F, Docx, C, Patel, V, Green, AC, Viant, M,
Lukaszewski, R & Dunn, W 2019, 'Multiple metabolic pathways are predictive of ricin intoxication in a rat model',
Metabolomics, vol. 15, no. 7, 102. https://doi.org/10.1007/s11306-019-1547-9
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Contains public sector information licensed under the Open Government Licence v3.0.
D’Elia, R.V., Goodchild, S.A., Winder, C.L. et al. Metabolomics (2019) 15: 102. https://doi.org/10.1007/s11306-019-1547-9
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Vol.:(0123456789) 
Metabolomics (2019) 15:102 
https://doi.org/10.1007/s11306-019-1547-9
ORIGINAL ARTICLE
Multiple metabolic pathways are predictive of ricin intoxication 
in a rat model
Riccardo V. D’Elia1 · Sarah A. Goodchild1 · Catherine L. Winder2 · Andrew D. Southam2 · Ralf J. M. Weber2 · 
Fiona M. Stahl1 · Cerys Docx1 · Vikesh Patel1 · A. Christopher Green1 · Mark R. Viant2 · Roman A. Lukaszewski1 · 
Warwick B. Dunn2,3
Received: 21 December 2018 / Accepted: 28 March 2019 / Published online: 3 July 2019 
© Crown 2019
Abstract
Introduction Exposure to ricin can be lethal and treatments that are under development have short windows of opportunity 
for administration after exposure. It is therefore essential to achieve early detection of ricin exposure to provide the best 
prognosis for exposed individuals. Ricin toxin can be detected in clinical samples via several antibody-based techniques, but 
the efficacy of these can be limited due to the rapid processing and cellular uptake of toxin in the body and subsequent low 
blood ricin concentrations. Other diagnostic tools that perform, in an orthogonal manner, are therefore desirable.
Objectives To determine time-dependent metabolic changes in Sprague–Dawley rats following intravenous exposure to ricin.
Methods Sprague–Dawley rats were intravenously exposed to ricin and multiple blood samples were collected from each 
animal for up to 48 h following exposure in two independent studies. Plasma samples were analysed applying HILIC and 
 C18 reversed phase UHPLC–MS assays followed by univariate and multivariate analysis.
Results In Sprague–Dawley rats we have demonstrated that metabolic changes measured in blood can distinguish between 
rats exposed intravenously to ricin and controls prior to the onset of behavioral signs of intoxication after 24 h. A total of 
37 metabolites were significantly altered following exposure to ricin when compared to controls. The arginine/proline, bile 
acid and triacylglyceride metabolic pathways were highlighted as being important with two triacylglycerides at 8 h post 
exposure giving an AUROC score of 0.94. At 16 h and 24 h the AUROC score increased to 0.98 and 1.0 with the number of 
metabolites in the panel increasing to 5 and 7, respectively.
Conclusions These data demonstrate that metabolites may be a useful tool to diagnose and detect ricin exposure, thus increas-
ing the effectiveness of supportive therapy and future ricin-specific medical treatments.
Keywords Ricin · Metabolomics · Arginine/proline metabolism · Bile acid metabolism · Triacylglyceride metabolism
1 Introduction
Ricinus communis, the castor bean plant, is indigenous to 
Eastern Africa, but is found commonly across the globe 
(Prince 2000). The castor oil obtained from the plant’s seeds 
is used in many products such as hydraulic fluid, engine 
lubricant and even in traditional medicine (Patel et al. 2016). 
The seeds also contain the toxic plant protein ricin (Schep 
et al. 2009) which belongs to the type 2 ribosome-inactivat-
ing protein (RIP) family and consists of two chains; Ricin 
Toxin A-chain (RTA) and Ricin Toxin B-chain (RTB) (Lord 
et al. 1994). The A-chain is a N-glycosidase enzyme respon-
sible for the toxicity of ricin, while the B-chain facilitates 
entry into the cell by binding to cell surface glycolipids 
and proteins (Olsnes 2004). Once within the cell the RTA 
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subunit is transported to the cytosol where it specifically tar-
gets a conserved adenine residue found in the 28S ribosomal 
RNA of the 60S subunit. This leads to inhibition of protein 
synthesis and ultimately cell apoptosis (May et al. 2013).
The  LD50 of ricin is thought to be between 3 and 30 µg/kg 
in humans (Worbs et al. 2011) and in rodent models between 
2 and 8 µg/kg (Roy et al. 2012) but can vary dependent 
on route of administration (i.e. intravenous vs. inhalation 
vs. ingestion) and dose. This high toxicity, along with the 
availability of the plant, its seeds, and relative ease of ricin 
extraction has lead ricin to be listed as a Category B threat 
agent by the United States Center for Disease Control (Khan 
et al. 2000; Rotz et al. 2002) and declared as a Schedule 1 
agent by the Chemical Weapons Convention (CWC) (Kuca 
and Pohanka 2010). Indeed ricin has been used for assassina-
tion (Crompton and Gall 1980) and in several postal threats 
(Schier et al. 2007).
Currently, there are no specific treatments for ricin intoxi-
cation, however pre-clinical studies have demonstrated the 
utility of polyclonal or monoclonal ricin-neutralising anti-
bodies (anti-toxin) to treat the intoxication (Gal et al. 2017; 
Van Slyke et al. 2016; Whitfield et al. 2017), although these 
are not yet licensed for clinical use. Data suggests that effi-
cacy of these antibody therapies is significantly reduced if 
they are not given very early post exposure (Griffiths et al. 
2007; Pratt et al. 2007). Other therapeutic strategies have 
been explored including “disease modifying” compounds 
which involve using inhibitors that target specific bio-
chemical pathways such as the cytokine storm [Reviewed 
by D’Elia et al. (2013) and Gal et al. (2017)] to alleviate 
symptoms. The requirement for medical countermeasures 
for ricin intoxication to be administered early, combined 
with the short therapeutic window of pre-clinical therapies, 
highlights the requirement for early detection and diagnosis.
Early diagnosis of intoxication is essential to ensure that 
medical care and therapy are given in a timely manner as 
treatment efficacy can be reduced dramatically following 
the presentation of signs and symptoms. The generation of 
diagnostic tools, that can identify intoxication at the very 
early stages or even before changes in behavioral pheno-
types, to stratify populations related to risk, are required to 
guide administration of therapy in the most effective way 
(Lukaszewski et al. 2008). This is of particular importance 
for acute diseases, including those caused by biological and 
toxin threat agents, where exposure can cause severe mor-
bidity and mortality in days or even hours. This task is made 
even more difficult if the agent is unknown or is not detect-
able or cultureable (Patocka and Streda 2006; Ristanovic 
2009).
The most common ricin detection methods rely on anti-
body recognition techniques such as enzyme linked immu-
nosorbent assays (ELISA), flow cytometry and immuno-
PCR (Kim et al. 2009; Men et al. 2010; Poli et al. 1994) to 
directly detect the toxin in clinical samples. ELISAs can be 
very sensitive being able to detect ricin at levels as low as 
20 pg per 100 μl of tissue extract (Leith et al. 1988). They 
can also be highly adaptable showing efficacy in multiple 
clinical specimens and environmental samples including 
blood, urine and stool (Chen et al. 2014). The uptake of 
ricin into tissues is rapid (Moshiri et al. 2016). In addi-
tion, processing of ricin in the body differs depending on 
the route of exposure (Griffiths 2011). As a consequence, 
selecting the most appropriate sample type to test within 
the small window for detection of toxin after exposure has 
occurred remains a considerable challenge (Griffiths 2011). 
DNA analysis techniques have also been shown to be effec-
tive in detecting toxin exposure indirectly by exploiting the 
mechanism of action where ricin inhibits protein synthesis 
by removing an adenine from the 28S rRNA (Diakite et al. 
2015; Pierce et al. 2011). More recently, “omic” techniques 
such as transcriptomics and proteomics, which are not only 
able to look at agent products, but also specific biomarkers 
of intoxication have been applied to models of intoxication. 
Indeed, a proteomic study where mice were exposed to aero-
solised ricin highlighted that 6 mouse proteins were highly 
associated with ricin intoxication (Guo et al. 2014). The 
recent development of another “omic” technology, metabo-
lomics, has the potential to be a complementary new tech-
nology (Dunn et al. 2011).
In the study reported here we sought to determine, in 
an intravenous rat model of ricin intoxication, whether a 
metabolomics approach could identify perturbed metabolic 
pathways prior to the onset of an adverse clinical phenotype. 
The discovery of putative biomarkers of exposure could then 
be validated in future investigations. Furthermore, such 
knowledge could increase the mechanistic understanding of 
ricin toxicity, beyond protein synthesis inhibition, thereby 
contributing to the development of an adverse outcome path-
way (Hamm et al. 2017).
2  Materials and methods
2.1  Ricin stock preparation
Ricinus Communis Zanzibariensis toxin variant E was sup-
plied by Dstl (batch 1124/29/1/1) at 2.7 mg/ml in  Ca2+ and 
 Mg2+-free phosphate buffered saline (PBS, GIBCO). The 
purity of this preparation was > 90% by SDS-PAGE and 
densitometry following Coomassie brilliant blue staining. 
Ricin was stored at − 80 °C prior to use.
2.2  Animals
All work was conducted under Home Office licence 30/3269. 
Sprague–Dawley rats were supplied by Charles River UK. 
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Animals were pre-implanted with an identification/tempera-
ture chip. Animals were housed in the experimental ani-
mal house for 2 weeks prior to surgery with food and water 
ad libitum.
2.2.1  Surgery
All animals were surgically prepared with a vascular access 
button (VAB) connected to the carotid artery to enable blood 
sampling. Pre-medication analgesia was administered 1 h 
prior to surgery (Metacam 2 mg/ml s.c.). Anaesthesia was 
induced with 5% isoflurane in an induction box. The rats 
were moved to a nose cone as the surgical fields were close-
clipped. They were then placed in a supine position on a 
heating pad and surgical fields were cleaned with chlorhex-
idine scrub solution. Anaesthesia was maintained with 2–5% 
Isoflurane (levels were determined by close monitoring of 
heart rate, respiration rate and level of response to exter-
nal stimuli by a trained anaesthetist throughout the surgical 
procedure).
An incision (approximately 25 mm) was made on the 
ventral surface of the neck. A subcutaneous pocket was cre-
ated by blunt dissection and then the left carotid artery was 
located and isolated. Two suture ligatures (Mersilk 6-0) were 
placed loosely around the blood vessel. The distal ligature 
was tied off and tension applied to the ligature in order to 
keep the vessel taut and straight during the cannulation. An 
atraumatic vessel clamp was used to prevent bleeding as 
the vessel was cannulated using a 2Fr polyurethane catheter 
pre-filled with 5 IU heparin in 0.9% saline. The catheter was 
secured in place with the pre-placed suture ligatures (above 
and between the suture rings on the catheter). The catheter 
patency was checked with a 5 IU heparin solution (< 10 µL). 
The catheter was then temporarily clamped and then capped 
with an appropriately sized pin. The catheter was tunnelled 
sub-cutaneously to the midline area on the dorsal surface, 
approximately 1 cm caudal to the base of the skull. The 
ventral incision was closed using 4/0 Vicryl suture. With the 
animal back in the prone position, the catheter was trimmed 
to the required length and connected to the VAB. 4/0 Mersilk 
was used to secure the catheter to the button. The VAB was 
then inserted under the skin and the wound closed with 4/0 
Vicryl. Once surgery was complete, the line was checked, 
flushed and locked with a lock solution (500 IU heparin in 
50% glucose in 0.9% saline). Rats received 5 ml fluids (Veti-
vex 18 s.c.) and were placed in a warm (29 °C) recovery box 
and monitored until fully recovered.
2.2.2  Study protocol
Following a recovery period of 6–7 days post-surgery in 
the home cage, rats were moved to the experimental room. 
A total of 24 rats over two independent experiments were 
studied for the metabolomics analysis (six rats in a discovery 
study (all ricin exposed) and sixteen in a validation study (8 
ricin exposed vs. 8 PBS control, a complete set of samples 
could not be collected from one ricin-exposed rat due to 
a blocked catheter and this animal was omitted from the 
metabolomic analysis)). An additional 17 rats were chal-
lenged with ricin in a pilot study (n = 5) and for toxicoki-
netic measurements (n = 12) to determine the concentration 
of detectable ricin in the blood post exposure using ELISA 
(up to 24 h). Clinical signs data (bodyweight, temperature 
and clinical score) were collected for all 31 ricin-exposed 
rats and the 8 exposed to PBS. Statistical comparisons were 
made only to compare the PBS and the corresponding, time-
matched, ricin-exposed animal data for weights and temper-
atures for the validation study (GraphPad Prism version 6.00 
for Windows, GraphPad Software, La Jolla California USA). 
Animals from the pilot study and the discovery metabo-
lomics study were used to follow the progression of intoxi-
cation up to a predetermined humane endpoint (see below). 
Rats in the toxicokinetic and validation metabolomics study 
were humanely killed at 24 and 32 h respectively. Only 10 
out of 12 rat blood samples were used for ELISA analysis 
due to the vascular access buttons in 2 animals not func-
tioning correctly. The total blood volume of each rat was 
estimated at the start of the experiment assuming a volume 
of 70 ml·kg−1 (Morton et al. 1993). A maximum of 15% 
total blood volume was taken from each rat over the course 
of the study.
Rats were placed in a heated chamber (39 °C) for up 
to 10 min before being restrained for dosing. Ricin was 
administered at a dose of 8 µg·kg−1 and a dose volume of 
1 ml·kg−1 via the tail vein. This dose is expected to be ~ 1–2 
 LD50 (Franz 1997) and was chosen for this study to ensure 
the animals would have developed an adverse behavioural 
phenotype longer term. To confirm this, animals were 
monitored for signs of intoxication for up to 72 h after ricin 
administration. Rats were then moved into the metabolism 
cages and connected to an automated blood sampling sys-
tem (ABS, Instech Solomon, USA). For the metabolomics 
studies samples were taken at − 16 h (pre-exposure baseline 
control), 0 h (time of exposure), 1 h, 8 h, 16 h, 24 h, 32 h 
and 48 h post exposure though later time points were not 
analysed because of severe intoxication and humane killing. 
For the toxicokinetic ELISA studies, samples were taken at 
5 min, 20 min, 1 h, 5 h, 8 h and 24 h post exposure. Whole 
blood was used for ELISA analysis and plasma was prepared 
for metabolomics analysis. Rats were observed hourly and 
scored for signs of intoxication (behavioral phenotype). The 
indicators noted were condition of coat (e.g. ruffled), pos-
ture (hunched), mobility and pinching (drawing in of the 
abdomen). A score of 0 was assigned if signs were normal 
(no change to controls), 1 = minor alterations and 2 = severe 
signs. Body temperature (via an implanted identity chip) was 
 R. V. D’Elia et al.
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also taken hourly. Any animal scored as severely intoxicated 
for all signs, i.e. a score of 8, was humanely killed by a 
schedule 1 method.
2.3  Toxicokinetics
Ricin ELISA kits (MP Biomedical) were kindly supplied 
by DST-G (Australia) and DSO National Laboratories (Sin-
gapore) for use in this work. The development of this assay 
is described in (Chen et al. 2014) and consists of a 32-well 
ELISA plate pre-coated with ricin-A chain specific mono-
clonal antibodies RA999 (Meridian Life Science, USA) and 
7G12, (US Army Medical Research Institute of Infectious 
Diseases (Dertzbaugh et al. 2005). Blood samples from 
each exposed animal (30 μl) were added to 60 μl of Sam-
ple treatment buffer (STB) pre-aliquoted into the wells of a 
non-binding microwell plate. Control samples (kit-supplied 
positive and negative samples) were prepared similarly. Each 
ELISA plate was also used to analyse a range of known ricin 
concentrations prepared in naive whole blood. This method-
ology was used to generate standard curves to enable quanti-
fication of ricin within ex vivo samples. Samples containing 
known ricin concentrations were prepared by serial dilution 
of a known ricin standard and were treated in the same man-
ner as described above.
The samples and controls were incubated at room tem-
perature for 10 min. The biotinylated secondary antibody 
(kit-supplied rabbit polyclonal antibody raised against ricin 
toxoid, Toxin Technology, USA) was prepared by adding 
1.6 ml of deionised water to the vial followed by gentle 
swirling to avoid foaming. The secondary antibody (25 μl) 
was then added to all wells of the ELISA plate, followed by 
75 μl of the treated samples or controls from the non- bind-
ing plate. The loaded ELISA plate was then covered and 
incubated at 37 °C for 60 min. The plate was then washed 
6 times with 250 μl of diluted wash buffer (kit-supplied) 
per well. A freshly made working solution of streptavidin 
peroxidase conjugate (Kit-supplied, 100 μl per well) was 
then added and the plate incubated at room temperature, 
for 10 min. The plate was washed again as above, and TMB 
reagent (kit-supplied, 100 μl) per well added. The plate was 
covered and incubated in the dark for 10 min. Stop buffer 
(2 M sulphuric acid; 50 μl/well) was added and the plate was 
gently agitated and read (within 10 min) at 450 nm and at a 
reference wavelength at 620 nm.
Readings taken at 620 nm were subtracted from read-
ings at 450 nm. If the ELISA has performed well, the mean 
of the corrected absorbance readings of non-reactive con-
trols should be equal to or below 0.1 units of OD. For the 
corrected reactive control values, these must be equal to or 
greater than 1.0 OD units. In addition, the cut off value for 
the assay, below which the sample data is excluded, is 2 × the 
mean of the nonreactive control.
2.4  Analysis of toxicokinetic data
Readings taken from the samples containing known concen-
trations of ricin were used to generate a standard curve. Data 
was background subtracted and fitted with a 4-parameter 
logistic non-linear curve fit (Eq. 1) using GraphPad Prism 
(Version 6 for Windows). No weighting was applied during 
curve fitting. Ricin concentrations in individual biological 
samples were interpolated from the curve fit using GraphPad 
Prism. Toxicokinetic data were analysed by fitting one and 
two phase exponential decays to the data and an extra sum 
of squares F-test was used to compare the fits (GraphPad 
Prism).
where Bottom = bottom plateau of curve fit, Top = top pla-
teau of curve fit.
2.5  Metabolomics study
2.5.1  Sample preparation
Plasma samples were extracted to separate low molecular 
weight metabolites from other biochemicals including pro-
teins, RNA and DNA. Samples were thawed and extracted 
on ice. For the analysis of water-soluble metabolites, 180 
µL of acetonitrile (LC–MS grade, LiChrosolv, Merck) was 
added to 60 µL of plasma followed by vortex mixing (15 s), 
centrifugation (13,000×g, 15 min) and transfer of the clear 
supernatant to a glass LC autosampler vial (VI-04-12-
02RVG 300μL Plastic, Chromatography Direct, UK). For 
the analysis of lipid metabolites, 180 µL of isopropyl alco-
hol, IPA (LC-MS grade, LiChrosolv, Merck) was added to 
60 µL of plasma followed by vortex mixing (15 s), centrifu-
gation (13,000×g, 15 min) and transfer of the clear superna-
tant to a glass LC autosampler vial (VI-04-12-02RVG 300μL 
Plastic, Chromatography Direct, UK). A single pooled QC 
sample was prepared by combining 25 µL aliquots of all 
biological samples where adequate sample volume remained 
and vortex mixing (2 min). Aliquots (60 µL) of the pooled 
QC sample were extracted as defined above.
2.5.2  Ultra high performance liquid chromatography‑mass 
spectrometry
The samples were analysed applying two Ultra High Per-
formance Liquid Chromatography-Mass Spectrometry 
(UHPLC-MS) methods using a Dionex UltiMate 3000 Rapid 
Separation LC system (Thermo Fisher Scientific, MA, USA) 
coupled with a heated electrospray Q Exactive Focus mass 
spectrometer (Thermo Fisher Scientific, MA, USA). Polar 
(1)
Y = Bottom + (Top − Bottom)∕(1 + 10 (̂(LogEC50-X) × HillSlope))
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extracts were analysed on a Accucore-150-Amide-HILIC 
column (100 × 2.1 mm, 2.6 μm, Thermo Fisher Scientific, 
MA, USA). Mobile phase A consisted of 10 mM ammo-
nium formate and 0.1% formic acid in 95% acetonitrile/water 
and mobile phase B consisted of 10 mM ammonium for-
mate and 0.1% formic acid in 50% acetonitrile/water. Flow 
rate was set for 0.50 ml·min−1 with the following gradient: 
t = 0.0, 1% B; t = 1.0, 1% B; t = 3.0, 15% B; t = 6.0, 50% 
B; t = 9.0, 95% B; t = 10.0, 95% B; t = 10.5, 1% B; t = 14.0, 
1% B, all changes were linear with curve = 5. The column 
temperature was set to 35 °C and the injection volume was 
2 μL. Data were acquired in positive and negative ionisation 
modes separately within the mass range of 70–1050 m/z at 
resolution 70,000 (FWHM at m/z 200). Ion source param-
eters were set as follows: Sheath gas = 53 arbitrary units, 
Aux gas = 14 arbitrary units, sweep gas = 3 arbitrary units, 
Spray Voltage = 3.5 kV, Capillary temp. = 269 °C, Aux gas 
heater temp. = 438 °C. Data dependent MS2 in ‘Discovery 
mode’ was used for the MS/MS spectra acquisition using 
following settings: resolution = 17,500 (FWHM at m/z 200); 
Isolation width = 3.0 m/z; stepped normalised collision ener-
gies (stepped NCE) = 25, 60, 100%. Spectra were acquired 
in three different mass ranges: 70–200 m/z; 200–400 m/z; 
400–1000 m/z.
Non-polar extracts were analysed on a Hypersil GOLD 
column (100 × 2.1 mm, 1.9 µm; Thermo Fisher Scientific, 
MA, USA). Mobile phase A consisted of 10 mM ammo-
nium formate and 0.1% formic acid in 60% acetonitrile/
water and mobile phase B consisted of 10 mM ammo-
nium formate and 0.1% formic acid in 90% propan-2-ol/
water. Flow rate was set for 0.40 ml·min−1 with the follow-
ing gradient: t = 0.0, 20% B; t = 0.5, 20% B, t = 8.5, 100% 
B; t = 9.5, 100% B; t = 11.5, 20% B; t = 14.0, 20% B, all 
changes were linear with curve = 5. The column tempera-
ture was set to 55 °C and the injection volume was 2μL. 
Data were acquired in positive and negative ionisation mode 
separately within the mass range of 150 – 2000 m/z at reso-
lution 70,000 (FWHM at m/z 200). Ion source parameters 
were set as follows: Sheath gas = 50 arbitrary units, Aux 
gas = 13 arbitrary units, sweep gas = 3 arbitrary units, Spray 
Voltage = 3.5 kV, Capillary temp. = 263 °C, Aux gas heater 
temp. = 425 °C. Data dependent MS2 in ‘Discovery mode’ 
was used for the MS/MS spectra acquisition using follow-
ing settings: resolution = 17,500 (FWHM at m/z 200); Iso-
lation width = 3.0 m/z; stepped normalised collision ener-
gies (stepped NCE) = 20, 50, 80%. Spectra were acquired 
in three different mass ranges: 200–400 m/z; 400–700 m/z; 
700–1500 m/z.
A Thermo ExactiveTune 2.8 SP1 build 2806 was used 
as instrument control software in both cases and data were 
acquired in profile mode. Quality control (QC) samples were 
analysed as the first ten injections and then every seventh 
injection with two QC samples at the end of the analytical 
batch. Two blank samples were analysed, the first as the 6th 
injection and then the second at the end of each batch.
2.5.3  Raw data processing
Raw data acquired in each analytical batch were converted 
from the instrument-specific format to the mzML file format 
applying the open access ProteoWizard software (Kessner 
et al. 2008). Deconvolution was performed with XCMS 
software according to the following settings of Min peak 
width (4 for HILIC and 6 for lipids); max peak width (30); 
ppm (12 for HILIC and 14 for lipids); mzdiff (0.001); gap-
Init (0.5 for HILIC and 0.4 for lipids); gapExtend (2.4); bw 
(0.25); mzwid (0.01) (Smith et al. 2006). A data matrix of 
metabolite features (m/z-retention time pairs) vs. samples 
was constructed with peak areas provided where the metabo-
lite feature was detected for each sample. Putative annotation 
of metabolites or metabolite groups was performed by apply-
ing the PUTMEDID-LCMS workflows operating in the Tav-
erna workflow environment (Brown et al. 2011). We applied 
5 ppm mass error and a retention time range of 2 s in feature 
grouping and molecular formula and metabolite matching. 
As different metabolites can be detected with the same accu-
rate m/z (for example, isomers with the same molecular for-
mula), multiple annotations could be observed for a single 
detected metabolite feature. Also, a single metabolite could 
be detected as multiple molecules, particularly as a different 
type of ion (e.g., protonated and sodiated ions). Through-
out this article, the term “metabolite” refers to either single 
metabolites or groups of molecules with the same reten-
tion time and the same accurate m/z. All molecules were 
annotated according to guidelines for reporting of chemical 
analysis results, specifically to Metabolomics Standards Ini-
tiative level 2 (Sumner et al. 2007).
2.5.4  QC filtering and multivariate data analysis
The data for pooled QC samples were applied to perform 
QC filtering. For each metabolite feature detected QC sam-
ples 1–8 were removed and the relative standard deviation 
and percentage detection rate were calculated. Metabolite 
features with a RSD > 30% and a percentage detection rate 
< 60% were deleted from the dataset. Missing values in the 
data were replaced by values applying k nearest neighbour 
(kNN) missing value imputation followed by normalisation 
to sample total peak area (as a percentage), glog transforma-
tion and Pareto scaling prior to data analysis. Principal Com-
ponents Analysis (PCA) was then performed to assess the 
technical variability (measured by the replicate analysis of a 
pooled QC sample) and biological variability as part of the 
quality control process. Areas under the Receiver Operator 
Curves (AUROC) were calculated in MetaboAnalyst with 
multiple metabolites combined (Xia et al. 2015).
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2.5.5  Univariate data analysis
Data were normalised to sample total peak area (as a per-
centage) and were defined as normalized concentration (%), 
no missing value imputation or scaling was performed and 
glog transformation was performed prior to data analysis. 
For the initial discovery study, paired within-subject t-tests 
were applied to define changes in metabolite concentra-
tions over time (up to 48 h). For the validation study which 
included unexposed control animals, ‘Within-subjects 
repeated measures ANOVA’ was applied to investigate 
time-specific statistically significant changes (up to 32 h), 
phenotype-specific statistically significant changes and 
time × phenotype interactions which were statistically sig-
nificant, in the software MetaboAnalyst (Guo et al. 2016). 
All statistical analyses are reported following correction for 
multiple testing applying the Benjamin-Hochberg method. 
All metabolite features which were statistically significant 
in both the discovery and validation datasets were passed 
forward for further interpretation with all other metabolite 
features being removed from the datasets. Following this, 
multiple replicates of the same metabolite features were fil-
tered to leave one replicate with the p value furthest from 
0.05.
3  Results
3.1  Model development
Previous data were utilised to determine the most appropri-
ate i.v. ricin dose for rats for a metabolomics study. Depend-
ing on the dose of ricin, morbidity and mortality onset varied 
between hours and days (data not shown). It was decided 
that a dose where the majority of rats showed clinical or 
behavioural signs of ricin intoxication, but did not succumb 
to intoxication within 48 h of exposure would be suitable. 
This dose was estimated to be 8 µg·kg−1. This progression 
of intoxication would allow for multiple samples to be taken.
3.1.1  In‑vivo signs of intoxication
Data relating to signs of intoxication are reported. All rats 
gradually gained weight during their acclimatisation to the 
housing in the experimental animal house; they showed 
a small decrease, on average, following surgery but then 
gained weight steadily until challenge with ricin. Following 
exposure, rats in both the PBS and ricin-exposed groups 
gradually lost weight. There was no statistically significant 
difference between the two groups and weight loss at this 
point is likely to be due to stresses of handling for exposure 
and blood sampling. Ricin-exposed animals in the pilot and 
discovery metabolomics study continued to lose weight until 
the humane end point or the end of the study (Fig. 1). Fol-
lowing intoxication, temperature readings were taken hourly 
and increased, on average, by 1 °C from 6 h post challenge 
in all ricin exposed rats (Fig. 1B). Comparison of PBS and 
corresponding ricin-exposed animals from the validation 
study shows that this change is statistically significant at the 
6 and 8 h time points, (p < 0.001 and p < 0.01 respectively). 
From ~ 30 h after intoxication, temperatures became quite 
variable and dropped to below normal ranges in some ani-
mals (Fig. 1B). This is also consistent with the appearance 
of behavioral signs of intoxication which started as minor 
observed signs in the majority of animals between 20 and 
30 h after intoxication (Fig. 1C). Clinical signs of intoxica-
tion in the remaining animals gradually increased in sever-
ity and animal numbers drop during this time course as the 
rats reached the pre-determined humane endpoint of severe 
intoxication showing that the ricin dose of 8 µg·kg−1 causes 
a lethal intoxication in Sprague–Dawley rats (Fig. 1D).
3.1.2  Ricin toxicokinetics
Using standard ELISA techniques the concentration of ricin 
in blood following i.v. ricin exposure was determined. Data 
demonstrated that free ricin was rapidly removed from the 
blood in a biphasic manner (Fig. 2 and Table 1). Ricin levels 
in the blood were below the limit of detection of this ELISA 
(n = 10 rats) at ~ 5 h post exposure (Fig. 2). This is prior to 
the appearance of behavioral signs of intoxication (Fig. 1), 
which started to become apparent in the majority of rats 
administered this dose of ricin between about 20 h and 30 h 
after exposure in this study albeit at a minor level of clini-
cal score initially (Fig. 1C). A lack of observable behavio-
ral signs of intoxication at this 5 h point means there is a 
window of opportunity for metabolic biomarkers to provide 
an additional route to identifying whether individuals have 
been exposed to ricin, to complement direct toxin detection 
methods. 
3.2  Metabolic response to ricin exposure
An untargeted metabolomics approach applying UHPLC-
MS to measure water-soluble and lipid metabolites was per-
formed to investigate the dynamic response to ricin exposure 
for greater than 1000 metabolites in rat plasma. Two inde-
pendent studies were performed to enable the discovery and 
subsequent validation of metabolic changes to increase the 
reliability of the results reported. 163 and 363 metabolites 
were statistically significant in the discovery and valida-
tion studies, respectively. Statistical significance between 
different timepoints is reported for ricin-treated rats in the 
discovery study and statistical significance between control 
and ricin-treated rats is reported for the validation study. 
Following comparison of the results for these two studies, 
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37 metabolites were identified as statistically significant in 
both studies (Table 2).
Metabolites were grouped into metabolic pathways/
metabolite classes. It is important to note that multiple 
metabolites in each pathway/class were calculated to be 
statistically significant but not all metabolites in each path-
way/class. Therefore these results indicate which metabolic 
pathways/metabolite classes warrant further investigation 
Fig. 1  Effect of ricin exposure 
on bodyweight, temperature, 
signs of intoxication and 
survival. Data from up to 31 
ricin-exposed rats are shown as 
mean ± SD (panel A and B) and 
median for Panel C (red data 
points) and for individual rats 
(grey data points in all panels) 
for bodyweight (panel A), body 
temperature (panel B) and clini-
cal score (panel C). Data for 
PBS-exposed rats are shown as 
blue data points as mean ± SD 
and median only. Bodyweight 
data are normalised to t = 0, the 
time-point at which the ricin 
(8 µg·kg−1 i.v.) challenge was 
administered. Clinical scores 
data (panel C) are calculated 
from those rats alive at each 
time point. On reaching the 
humane endpoint (score = 8) or 
the end of the study (see panel 
D) rats are excluded from this 
analysis. Survival data for all 
animals in the study are shown 
in panel D, planned euthanasia 
at the experiment end-point is 
indicated and these animals 
were censored from the analy-
sis. *Statistically significant 
difference between PBS and 
corresponding ricin-exposed 
animals in the validation study, 
p < 0.001 and p < 0.01 at 6 and 
8 h respectively, 2-way ANOVA 
and Sidak’s multiple compari-
sons test
A
B
C
D
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applying targeted analytical assays which measure all 
metabolites in these metabolic pathways/metabolite classes. 
Arginine and proline metabolism, bile acid metabolism, 
glycerophosphospholipid and triacylglyceride families 
were perturbed in both studies. The time-related changes 
in metabolite concentrations were investigated for these 
four metabolic pathways/metabolite classes. Triacylglycer-
ides demonstrated the quickest response to exposure with 
increases or decreases in their concentrations from 8 h and 
later (Fig. 3A). Bile acids demonstrated large increases in 
their concentrations from 16 h and later (Fig. 3B). Arginine 
and ornithine demonstrated concentration changes from 24 h 
with arginine showing a decrease (Fig. 3C) and ornithine 
showing an increase in concentration (Fig. 3D).
Multivariate AUROC analysis was performed for the 
validation study only because no control animals were 
included in the discovery study. Metabolites were assessed 
individually and in all possible combinations to identify the 
most powerful AUROC. An AUROC greater than 0.94 was 
observed at 8 h, 16 h and 24 h (Table 3). Caution should be 
taken relating to translation into human ricin intoxication 
because this is a well-controlled animal model study and 
human studies provide greater natural biological variability 
and potential confounders.
4  Discussion
Ricin toxin is a potential biothreat agent due to its ease of 
acquisition (castor bean plant) and lack of medical counter-
measures. Early detection and diagnosis of ricin intoxication 
is essential in reducing morbidity and mortality associated 
with the disease. This is made more difficult when ricin toxin 
rapidly binds to cells and is quickly taken up into cells and 
trafficked to the Golgi apparatus (Jenner et al. 2018) mean-
ing levels of detectable ricin in the blood are likely to be low.
Fig. 2  Ricin toxicokinetics 
following administration of 
8 µg·kg−1 ricin i.v. Data are 
shown as mean ± SD (red or 
blue points) from up to 10 
individual animals (grey points) 
at each time point (the vascular 
access buttons of 2 animals 
were not patent and no samples 
could be collected from these 
animals). In the upper panels, A 
and B, a limit of detection could 
be estimated from the blank 
absorbance plus 2 times its SD 
(horizontal line). Whilst this is 
indicative of a detection limit it 
is based on relatively few deter-
minations and for quantitative 
analysis of the ricin toxicokinet-
ics all ricin concentrations that 
could be interpolated from the 
standard curve were analysed 
(lower panels C, D). Curve fits 
shown are for 2 phase exponen-
tial decays, which in all cases 
provided statistically better fits 
to the data than a one phase 
model
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Table 1  Kinetic parameters describing disappearance of ricin from blood following in vivo administration of 8 µg kg−1 i.v. in rats
Values and 95% confidence intervals are shown in parentheses
Assay C0 (ng ml−1) t½ fast (h) t½ slow (h) % fast
ELISA 28.1 (15.5–40.7) 0.20 (0.11–1.25) 1.78 (1.31–2.77) 79.6 (66.1–93.0)
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In this study we confirm that when rats were exposed to 
ricin by the i.v. route standard ELISA techniques can only 
detect ricin in the blood at early time points post exposure 
(up to ~ 5 h post-exposure), the free toxin is quickly removed 
from the blood prior to overt signs of intoxication. None-
theless, and for the first time, we have demonstrated that 
Table 2  Annotated metabolites showing statistical significance in both the discovery and validation studies
The p value (following correction for multiple testing) and designated metabolite class/metabolic pathway are included to demonstrate enhance-
ment of specific metabolite class/metabolic pathway
Metabolites p value (discovery) p value (validation) Metabolite class
Ornithine 1.60E−03 7.23E−06 Arginine and proline metabolism
Arginine 3.35E−05 1.10E−14 Arginine and proline metabolism
β-Guanidinopropionic acid and/or Creatine 1.80E−03 8.71E−06 Arginine and proline metabolism
3-Indolepropionic acid and/or Indole-3-methyl acetate 3.00E−03 9.04E−17 Aromatic metabolism
Varanic acid 1.10E−03 4.86E−09 Bile acid metabolism
Taurallocholic acid and/or Tauro-b-muricholic acid and/
or Taurocholic acid and/or Taurohyocholate and/or 
Taurohyocholic acid and/or Tauroursocholic acid
1.69E−05 4.25E−11 Bile acid metabolism
3a,7b,12a-Trihydroxyoxocholanyl-Glycine and/or Gly-
cocholic acid
3.90E−03 1.82E−10 Bile acid metabolism
1,3,12-Trihydroxycholan-24-oic acid and/or 1b,3a,12a-
Trihydroxy-5b-cholanoic acid or isomer
2.10E−03 7.74E−10 Bile acid metabolism
Sulfolithocholylglycine 4.00E−05 3.55E−12 Bile acid metabolism
Taurochenodesoxycholic acid and/or Taurodeoxycholic 
acid and/or Tauroursodeoxycholic acid
4.50E−05 6.10E−12 Bile acid metabolism
3a,7b,12a-Trihydroxyoxocholanyl-Glycine and/or Gly-
cocholic acid
3.90E−03 4.44E−09 Bile acid metabolism
GalCer(d18:0/22:0) and/or GlcCer(d18:0/22:0) 1.60E−03 4.54E−15 Ceramides
GalCer(d18:1/24:1) and/or GlcCer(d18:1/24:1) 1.40E−03 3.00E−16 Ceramides
GalCer(d18:1/16:0) and/or GlcCer(d14:1/20:0) and/or 
GlcCer(d16:1/18:0) and/or GlcCer(d18:1/16:0)
1.00E−05 3.00E−16 Ceramides
PC[38:2] 4.60E−03 3.28E−06 Glycerophospholipid
PC[34:2] and/or PE-NMe[36:2] 8.00E−05 2.13E−13 Glycerophospholipid
PC[34:1] and/or PE-NMe2(O-16:0/O-16:0) 2.85E−05 2.70E−11 Glycerophospholipid
PC(16:0/5:0(CHO)) and/or LysoPC[20:2] and/or PC(O-
18:2/2:0)
1.90E−03 6.52E−07 Glycerophospholipid
PA[30:4] and/or PA[28:1] 1.90E−03 4.25E−05 Glycerophospholipid
LysoPE[22:1] 2.10E−03 4.48E−06 Lysoglycerophospholipid
LysoPC[22:1] 1.80E−03 1.86E−05 Lysoglycerophospholipid
LysoPC[20:2] and/or PC(O-18:2/2:0) 3.60E−03 3.17E−06 Lysoglycerophospholipid
LysoPC[24:1] 3.00E−05 1.80E−03 Lysoglycerophospholipid
Nicotinamide N-oxide and/or Urocanic acid 6.98E−06 7.70E−15 Mixed classes
3-Pyridinebutanoic acid and/or Norsalsolinol 7.27E−05 9.15E−15 Mixed classes
Beta-Tyrosine and/or Threo-3-Phenylserine and/or 
Tyrosine
1.60E−03 9.18E−06 Mixed classes
1-(2-Furanylmethyl)-1H-pyrrole 1.40E−03 9.15E−15 Other class
Isoleucyl-Valine and/or Leucyl-Valine 1.30E−03 1.31E−08 Peptide
SM(d18:2/24:1) and/or SM(d18:0/22:3) and/or 
SM(d16:1/22:0) and/or SM(d18:1/20:0) and/or
1.40E−03 1.28E−06 Sphingolipids
Cholesterol sulfate 6.00E−05 6.92E−08 Sterol and steroid (including Vitamin D) metabolism
3-Deoxyvitamin  D3 1.10E−03 3.17E−07 Sterol and steroid (including Vitamin D) metabolism
TG[60:9] 1.50E−03 1.20E−05 Triacylglyceride
TG[60:10] 8.00E−05 5.00E−05 Triacylglyceride
TG[54:6] and/or TG[53:6] and/or TG[51:3] and/
orTG[49:0]
8.10E−05 3.90E−03 Triacylglyceride
TG[53:8] and/or TG[51:5] and/or TG[50:2] and/or 
TG[47:1]
2.0E−03 5.50E−05 Triacylglyceride
TG[58:4] 3.16E−05 4.80E−03 Triacylglyceride
TG[49:3] 1.80E−03 2.15E−05 Triacylglyceride
 R. V. D’Elia et al.
1 3
102 Page 10 of 15
Fig. 3  Box and whisker plots 
defining the time-related 
concentration for selected 
metabolites following adminis-
tration of ricin i.v. Metabolites 
discovered as predictive of ricin 
exposure to rats using an untar-
geted metabolomics approach 
applying UHPLC-MS on blood 
samples. Samples were analysed 
at − 16 h (pre-exposure baseline 
control), 0 h (time of exposure), 
1 h, 8 h, 24 h, 32 h and 48 h 
post exposure for the discovery 
study. Samples were analysed at 
− 16 h (pre-exposure baseline 
control), 0 h (time of expo-
sure), 1 h, 8 h, 24 h and 32 h 
post exposure for the valida-
tion study. The seven box and 
whisker plots on the left are 
related to control animals (PBS 
exposed) and the seven box 
and whisker plots on the right 
are related to ricin exposed 
animals. Metabolites comprise 
TG[60:10] (panel A = dis-
covery and panel B = valida-
tion), sulfolithocholylglycine 
(panel C = discovery and 
panel D = validation), arginine 
(panel E = discovery and panel 
F = validation) and ornithine 
(panel G = discovery and panel 
H = validation)
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Fig. 3  (continued)
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metabolic changes are detectable at 8 h post exposure. 
This is important because this is at a time when ricin is not 
detectable by ELISA in this model, but is prior to signs of 
intoxication which become apparent at ~ 24 h, thus it could 
provide a trigger for administration of treatment within a 
time frame that would ensure efficacy of treatment. Spe-
cific metabolic pathways/metabolite classes were perturbed 
and a putative ricin toxin diagnostic biomarker panel has 
been identified. A total of 37 metabolites were statistically 
significantly changed in both the discovery and validation 
studies with 32 of these metabolites demonstrating the same 
dynamic time profiles in both studies. The significantly 
altered metabolites were heavily associated with arginine 
and proline metabolism, bile acid metabolism and the tria-
cylglyceride metabolite class.
Arginine and proline are amino acids and are therefore 
essential for a number of key functions within the body such 
as detoxification, embryonic survival and organ homeosta-
sis (Albaugh et al. 2017; Wu et al. 2009). The degradation 
of arginine produces proline, but also ornithine and cre-
atine, both of these latter metabolites were also identified 
as significantly altered metabolites following ricin expo-
sure. However due to the key nature of these amino acids, 
changes in the arginine and proline metabolic pathway and 
associated metabolites are seen in variety of diseases and 
injuries including sickle cell disease (Schnog et al. 2004), 
chronic kidney disease (Baylis 2006) and cancers (Ma et al. 
1999). A total of seven metabolites that were significantly 
altered following ricin exposure were associated with bile 
acid metabolism. Bile acids are produced in the liver, are 
released as glycine or taurine conjugates and are essential for 
the emulsification of lipids in the intestines, breakdown of 
cholesterol and nutrient absorption. Bile acids also have the 
ability to signal via interaction with receptors (Makishima 
et al. 1999) and control inflammation (Guo et al. 2016). 
Defects in bile acid metabolism, not surprisingly, lead to a 
variety of liver associated diseases, but also obesity and dia-
betes (Chavez-Talavera et al. 2017). The observed increase 
in bile acids could be indicative of toxicity effects on the 
liver or indicative of gut cell membrane changes leading to 
their increased permeability and further studies are required 
to investigate this. Triacylglycerides are the main constitu-
ents of fat deposits in adipocytes and other organs. They 
can be broken down by lipases and bile into smaller fatty 
acids to aid absorption. High levels of triacylglycerides are 
associated with metabolic disease, heart disease and stroke 
(Tao et al. 2016). As all of the metabolic pathways altered 
can be prognostic for human diseases, the diagnostic poten-
tial for these metabolites are therefore limited. However, the 
rapid changes over hours provides an opportunity to col-
lect and analyse multiple samples over 8 h and measure the 
change in concentration which will be quicker than with the 
chronic diseases listed above. When combined with known 
health status and risk of ricin exposure, greater successes of 
ricin intoxication diagnosis can be obtained.
The fact that arginine, bile acid and triacylglyceride 
metabolism are altered following exposure to ricin is not that 
surprising, especially when you consider the pathogenesis 
of the intoxication, where in rodent models there is severe 
weight loss and organ dysfunction following the apoptosis 
of cells. However, what is interesting is that the changes 
in these pathways and the corresponding metabolites are 
time specific and do not always follow the same pattern. 
The triacylglyceride metabolites are shown to be important 
at 8 h post exposure with two metabolites increasing and 
two metabolites decreasing. This is prior to any visually 
scored signs of intoxication being observed and was prior 
to weight loss in these animals. However, animal tempera-
tures increased within a few hours of exposure to ricin and 
therefore increases in lipolysis to release fatty acids for fatty 
acid beta-oxidation and ATP generation is the most prob-
able mechanism connecting temperature increase and tria-
cylglyceride changes. The bile acid metabolites, along with 
ceramides, show significant concentration changes at 16 h 
post ricin exposure, but all increase compared to controls. 
Arginine and proline metabolism is only perturbed at 24 h 
post exposure, with ornithine levels increasing and arginine 
levels decreasing. However at this point the rats were show-
ing signs associated to ricin intoxication.
Despite the disturbances being in common metabolite 
pathways it is the association of particular metabolic path-
ways with specific time points that has the potential to gen-
erate biomarkers that could be used in a pre-symptomatic 
or post-symptomatic setting. It is worth noting that the 
AUROC increases with time, but even at 8 h the combina-
tion of TG(54:6) and TG(60:10) gives a AUROC value of 
0.94. When 5 metabolites are combined (ornithine, arginine, 
urocanoic acid/isomer, cholesterol sulfate and sulfolitho-
cholylglycine) at 24 h post exposure the AUROC value is 
1.0. This would indicate that it is possible to diagnose ricin 
Table 3  Area under the receiver 
operator curve for putative 
biomarker panels applying 
multiple metabolites in each 
biomarker panel at 8 h, 16 h 
and 24 h
Time point (h) AUROC Metabolites included in biomarker panel
8 0.94 TG(54:6) and TG(60:10)
16 0.98 TG(54:6) and TG(60:10) and TG(60:9) and TG(58:4) and TG(53:8)
24 1.00 Ornithine and arginine and urocanic acid and/or isomer and choles-
terol sulphate and sulfolithocholylglycine
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exposure via the i.v route with 100% confidence compared to 
unchallenged controls from 8 h onwards. However, signifi-
cant toxic effects can occur early following exposure and a 
biomarker which is applicable from 1 h following exposure 
would be ideal to allow efficient management and treatment. 
It these scenarios a combination approach of using ELISA 
and metabolomics maybe applicable.
We are aware that there are some limitations to this 
study. I.V is not the most likely route of ricin exposure in 
the human population, but was chosen to ensure ricin was 
definitely in the system and would cause intoxication. Other 
routes including inhalation and ingestion are considered to 
be more likely, especially in a potential bioterrorism scenario 
(Schep et al. 2009). However for these proof-of-principle 
studies it was important to reduce variability in the animal 
model therefore the I.V route was selected. The relevance 
of all animal model data and human diseases is regularly 
discussed and can never be completely transferable. How-
ever, the metabolites identified are detected in human blood 
samples and due to the large fold changes seen in this rat 
study, there is a high likelihood that these changes would 
be seen in humans also. We are, in the case of ricin and 
other biological threat agents, very reliant on animal data, 
as conducting clinical trials is not possible and there tends 
to be few natural cases.
Additional studies must be conducted to further support 
these exciting findings, such as investigating different routes 
of exposure, lower sub-lethal challenge doses, and compar-
ing the data to related toxins. It will only then be possible to 
state that a highly-specific diagnostic biomarker for ricin has 
been discovered. Nonetheless the data presented here clearly 
demonstrates that metabolomics is a useful tool to identify 
putative biomarkers of exposure and to reveal new insights 
into the biochemical changes during the rodent response to 
ricin intoxication.
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